FitLife Brands Balances Irwin Boost With Margin Strain

Fitlife Brands ((FTLF)) has held its Q4 earnings call. Read on for the main highlights of the call.

FitLife Brands’ latest earnings call struck a cautiously balanced tone. Management highlighted a transformational boost from the Irwin Naturals acquisition and solid adjusted profitability, yet acknowledged persistent pressure in legacy brands, margins and demand. Investors heard a story of operational fixes underway, but also of near‑term uncertainty and a delayed timeline for a clean growth inflection.

Irwin Acquisition Drives Scale and Online Momentum

FitLife’s August 2025 purchase of Irwin Naturals provided the main growth engine in Q4. Irwin generated $12.6 million of revenue in the quarter, about 89% from wholesale, with roughly 6% organic growth after adjusting for lost Costco, Rite Aid and CBD business, and its Amazon channel ramped rapidly from about $60,000 in October to roughly $500,000 in December.

Headline Q4 Revenue Jumps on Deal Boost

Total company revenue reached $25.9 million in Q4 2025, up 73% year over year and largely driven by the consolidation of Irwin. While the growth headline is eye‑catching, management made clear that the uplift reflects acquisition math rather than a broad‑based cyclical rebound across the portfolio.

Wholesale Becomes the Growth Engine

Wholesale revenue surged to $15.5 million in Q4, representing 60% of total sales and a 213% jump versus the prior‑year period. The increase reflects Irwin’s wholesale skew and early cross‑selling, shifting the company’s mix away from its historically heavier reliance on online channels.

Adjusted Profitability Improves Despite Headwinds

On an adjusted basis, FitLife showed improving earnings power, with contribution rising 47% in Q4 2025 and adjusted EBITDA climbing 14% to $3.5 million. These gains suggest the business can scale profitably, even as reported net income is weighed down by deal‑related accounting and integration costs.

Deleveraging Track Record Strengthens Balance Sheet

The company continued to chip away at its debt load, paying down about $1.9 million of its term loan in Q4 and ending the year at $44.7 million of total debt. In early 2026, management further reduced the revolver by $1.4 million and made an additional term‑loan payment of roughly $1.5 million, saying they remain ahead of schedule on deleveraging.

Non-MRC Legacy Brands Show Resilient Growth

Outside of weaker banners, legacy FitLife brands excluding MRC and MusclePharm posted about 6% organic revenue growth for 2025. Within that group, online sales grew roughly 16% for the year and Q4 saw 4% organic growth with higher revenue, gross margin and contribution, underscoring underlying consumer demand where brand health remains intact.

Operational Overhaul Targets Irwin and Marketing

Management outlined several operational initiatives, including hiring a new vice president of operations for Irwin and a new chief marketing officer. Plans include extending Irwin product shelf life to three years, launching three new Irwin stock keeping units around Q3, boosting off‑Amazon demand generation and scaling cross‑selling into wholesale channels.

Early Wins From Cross-Selling MusclePharm

Leaning on Irwin’s salesforce, FitLife has already landed early cross‑sell victories, such as placing six MusclePharm products in a regional grocery chain. These initial wins hint at a broader opportunity to open new retail doors over time and to use Irwin’s reach to lift legacy brands.

Legacy FitLife Hit by Q4 Revenue and Margin Slippage

Legacy FitLife, including MRC and MusclePharm, posted Q4 revenue of $13.3 million, down 12% year over year with wholesale off 14% and online down 10%. Contribution fell 18% to $4.3 million and contribution margin slipped to 32.5% from 34.9%, highlighting pressure in the older portfolio despite pockets of strength.

MRC Remains a Drag on the Portfolio

Within legacy operations, the MRC brand group was a clear underperformer, with revenue down roughly 15% for full‑year 2025. Management framed MRC as the primary laggard in the portfolio, suggesting further work is needed to either stabilize or reposition the business.

Gross Margin Compresses With Irwin Mix Shift

Consolidated adjusted gross margin fell to 37.0% in Q4 2025 from 41.4% a year earlier when excluding inventory step‑up amortization. The decline largely reflects Irwin’s lower structural margins, with Irwin showing a 28.0% GAAP gross margin, or 33.2% on an adjusted basis, pulling down the blended company profile.

Net Income Dented by Deal Accounting

Net income declined to $1.6 million in Q4 2025 from $2.1 million in the prior‑year quarter, despite stronger adjusted metrics. The drop was mainly attributed to transaction‑related expenses and the final amortization of Irwin’s inventory step‑up, which was fully recognized in the quarter and should not recur.

Inventory Issues and Stockouts Constrain Irwin Upside

Irwin’s historic practice of short two‑year product dating and high minimum order quantities led to roughly $2 million per year in obsolete inventory write‑offs. Management also flagged stockouts, particularly in the first quarter, which limited sales to Amazon and key wholesale customers, underscoring the urgency of planned supply‑chain fixes.

Macro, Category and Amazon Dynamics Turn Tougher

Executives pointed to broad consumer discretionary softness and falling sentiment, noting that supplement category growth has recently turned negative. At the same time, Amazon’s algorithm changes have reduced visibility for brands with weaker off‑platform presence, driving subscription declines across most banners except Irwin, which is ramping from a small base.

Protein Cost Inflation Pressures MusclePharm Margins

MusclePharm, whose sales are roughly 80% protein products, was squeezed by surging whey protein concentrate prices approaching $11 per pound. Management said they declined about $1.5 million of low‑margin business rather than lock in poor economics, even as MusclePharm still managed around 5% organic revenue growth in 2025.

Guidance and Outlook: Growth Potential, Timing Unclear

Management declined to issue formal 2026 guidance, citing Q1 trends that were flat to slightly down versus Q4 and uncertainty around demand and supply‑chain fixes. They instead pointed investors to Q4’s 73% revenue growth, 37.0% adjusted gross margin, 47% contribution growth and $3.5 million adjusted EBITDA, and emphasized five priorities—supply‑chain repair, new products, off‑Amazon marketing, cross‑selling and SG&A efficiency—before offering detailed forecasts.

FitLife’s earnings call painted a picture of a company in transition, with the Irwin deal driving scale and adjusted profit growth while legacy brands, margins and macro forces weigh on the near term. Investors will be watching whether operational fixes and cross‑selling can convert today’s mixed results into a clearer, more durable growth and margin story once visibility improves.